Ekso Bionics Announces New Data to be Presented at 55th ISCoS Annual Scientific Meeting
September 12 2016 - 3:03PM
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton
company, today announced that the company and its collaborators
will have ten abstracts (one topical paper and nine posters) with
data from 116 patients presented at the International Spinal
Cord Society (ISCoS) Annual Scientific Meeting taking
place September 14-16, 2016 in Vienna, Austria. Of the
116 patients covered by these presentations, data from 54 patients
are from the Ekso Bionics-sponsored Pan-Euro Study.
The titles and schedule of posters and presentations are as
follows:
Topical Paper:
Topical Papers 2, 14 Sept 16, 11:40-1:10, Forum
(Parallel 3)
Dr. Willemijn Faber, Rehabilitation Physician,
Rehab Centre Heliomare: The Eksoskeleton - First clinical
experiences with spinal cord injury patients and measurement of
their energy expenditure in the Netherlands.
Poster Presentations (all in Exhibition/Poster/Catering
Area):
Session 1, 14 Sept 16, 10:35 - 11:35
and 3:10 - 4:10
- Mrs. Helene Nilsson,
Physiotherapist, Department of Rehabilitation
Medicine, Uppsala University Hospital: Effects of overground gait
training, using the robotic-exoskeleton Ekso™ and assessment of
gait parameters using the GAITRite®system. A pilot study.
Abstract #382
- Dr. Ashraf Gorgey, Director of The
Research, Hunter Holmes Mcguire VA Medical Center:
Exoskeleton Training and Physical Activity after Spinal Cord
Injury: A Case Series. Abstract #281
Session 2, 15 September 16, 9:50 - 10:45 and
3:10-4:10
- Dr. Ulla vig Nissen, Post
Doc., Clinic For Spinal Cord Injuries: Gait
progression in the Ekso™ robotic exoskeleton after eight weeks
training in participants with Spinal Cord Injury (Pan-Euro
Study). Abstract #172.
- Dr. Ashraf Gorgey, Director of The
Research, Hunter Holmes Mcguire VA Medical Center:
Exoskeletons and Rehabilitation after Spinal Cord Injury. Abstract
#410.
- Dr. Giulia Stampacchia, Medical Director
Centro Mielolesi, Medtronic: Psychological and
physical effort during robotic exoskeleton assisted walking on
treadmill and overground in SCI persons. Abstract #197.
Session 3, 16 Sept 16, 9:50-10:50 and
12:30-1:30
- Dr. Enrica Bonatti, Doctor, Montecatone
Rehabilitation Institute: Locomotor Training With Exoskeleton
EKSO-GT in Patients With Incomplete Motor Spinal Cord Injury in a
Hospital Setting- Preliminary Results. Abstract #199.
- Miss Kirsty Luard, Physiotherapy
Specialist, Hobbs Rehabilitation: A study
exploring the clinical effects of a short-duration exoskeleton
rehabilitation programme on key physiological markers in spinal
cord injury. Abstract #420.
- Mrs. Joanna Roziak, Physiotherapist,
Technomex: Results after six month of therapy using new robotic
devices after spinal cord injury: a case study. Abstract
#430.
- Mrs. Katherine Strausser, Sr. Controls
Engineer, Ekso Bionics Europe GmbH: Safety and
Efficacy of High-Dosage Use of Exoskeleton in Home Environment for
Chronic SCI: A Pilot Study. Abstract #67.
There will be eight additional posters at ISCoS that address the
functioning and benefits of exoskeletons in general. For more
detailed information, please visit:
www.iscosmeetings.org
Ekso Bionics will be exhibiting at booth numbers 13 and 15.
About Ekso Bionics® Ekso Bionics is a leading
developer of exoskeleton solutions that amplify human potential by
supporting or enhancing strength, endurance and mobility across
medical, industrial and defense applications. Founded in 2005, the
company continues to build upon its unparalleled expertise to
design some of the most cutting-edge, innovative wearable robots
available on the market. Ekso Bionics is the only exoskeleton
company to offer technologies that range from helping those with
paralysis to stand up and walk, to enhancing human capabilities on
job sites across the globe, to providing research for the
advancement of R&D projects intended to benefit U.S. defense
capabilities. The company is headquartered in the Bay Area and is
listed on the Nasdaq Capital Market under the symbol EKSO. For more
information, visit: www.eksobionics.com.
About Ekso™ GT
Ekso™ GT is the first
FDA cleared exoskeleton cleared for use with stroke
and spinal cord injuries from L5 to C7. The Ekso GT with
smart Variable Assist™ (marketed as SmartAssist outside the U.S.)
software is the only exoskeleton available for rehabilitation
institutions that can provide adaptive amounts of power to either
side of the patient’s body, challenging the patient as they
progress through their continuum of care. The suit’s patented
technology provides the ability to mobilize patients earlier, more
frequently and with a greater number of high intensity steps. To
date, this device has helped patients take more than 55 million
steps in over 120 rehabilitation institutions around the world.
Forward-Looking Statements Any statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements. Forward-looking
statements may include, without limitation, statements regarding
(i) the plans and objectives of management for future operations,
including plans or objectives relating to the design, development
and commercialization of human exoskeletons, (ii) a projection of
financial results, financial condition, capital expenditures,
capital structure or other financial items, (iii) the Company's
future financial performance and (iv) the assumptions underlying or
relating to any statement described in points (i), (ii) or (iii)
above. Such forward-looking statements are not meant to predict or
guarantee actual results, performance, events or circumstances and
may not be realized because they are based upon the Company's
current projections, plans, objectives, beliefs, expectations,
estimates and assumptions and are subject to a number of risks and
uncertainties and other influences, many of which the Company has
no control over. Actual results and the timing of certain events
and circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and
uncertainties. Factors that may influence or contribute to the
inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, the Company's inability to obtain
adequate financing to fund the Company's operations and necessary
to develop or enhance our technology, the significant length of
time and resources associated with the development of the Company's
products, the Company's failure to achieve broad market acceptance
of the Company's products, the failure of our sales and marketing
organization or partners to market our products effectively,
adverse results in future clinical studies of the Company's medical
device products, the failure to obtain or maintain patent
protection for the Company's technology, failure to obtain or
maintain regulatory approval to market the Company's medical
devices, lack of product diversification, existing or increased
competition, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC. To learn more about Ekso Bionics please visit us
at www.eksobionics.com. The Company does not undertake to
update these forward-looking statements.
Media Contact:
Carrie Yamond/Rajni Dhanjani
212-867-1788
cyamond@lazarpartners.com
Investor Contact:
Debbie Kaster
415-937-5403
investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2024 to May 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From May 2023 to May 2024